Logo image of ALGAE.PA

FERMENTALG (ALGAE.PA) Stock Fundamental Analysis

Europe - EPA:ALGAE - FR0011271600 - Common Stock

0.4905 EUR
-0.01 (-1.11%)
Last: 10/7/2025, 7:00:00 PM
Fundamental Rating

3

ALGAE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 71 industry peers in the Chemicals industry. ALGAE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALGAE shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALGAE has reported negative net income.
ALGAE had a negative operating cash flow in the past year.
ALGAE had negative earnings in each of the past 5 years.
In the past 5 years ALGAE always reported negative operating cash flow.
ALGAE.PA Yearly Net Income VS EBIT VS OCF VS FCFALGAE.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

ALGAE has a Return On Assets of -24.56%. This is amonst the worse of the industry: ALGAE underperforms 85.92% of its industry peers.
With a Return On Equity value of -38.02%, ALGAE is not doing good in the industry: 81.69% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -24.56%
ROE -38.02%
ROIC N/A
ROA(3y)-23.5%
ROA(5y)-19.63%
ROE(3y)-36.23%
ROE(5y)-31.43%
ROIC(3y)N/A
ROIC(5y)N/A
ALGAE.PA Yearly ROA, ROE, ROICALGAE.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

Looking at the Gross Margin, with a value of 20.94%, ALGAE is doing worse than 70.42% of the companies in the same industry.
In the last couple of years the Gross Margin of ALGAE has declined.
ALGAE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.82%
GM growth 5YN/A
ALGAE.PA Yearly Profit, Operating, Gross MarginsALGAE.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

4

2. Health

2.1 Basic Checks

ALGAE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALGAE has more shares outstanding
ALGAE has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALGAE has an improved debt to assets ratio.
ALGAE.PA Yearly Shares OutstandingALGAE.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ALGAE.PA Yearly Total Debt VS Total AssetsALGAE.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of 1.50, we must say that ALGAE is in the distress zone and has some risk of bankruptcy.
ALGAE has a Altman-Z score of 1.50. This is in the lower half of the industry: ALGAE underperforms 71.83% of its industry peers.
A Debt/Equity ratio of 0.12 indicates that ALGAE is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.12, ALGAE belongs to the top of the industry, outperforming 80.28% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z 1.5
ROIC/WACCN/A
WACC6.14%
ALGAE.PA Yearly LT Debt VS Equity VS FCFALGAE.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M 40M

2.3 Liquidity

ALGAE has a Current Ratio of 1.88. This is a normal value and indicates that ALGAE is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ALGAE (1.88) is better than 61.97% of its industry peers.
A Quick Ratio of 1.83 indicates that ALGAE should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.83, ALGAE belongs to the top of the industry, outperforming 83.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.88
Quick Ratio 1.83
ALGAE.PA Yearly Current Assets VS Current LiabilitesALGAE.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.44% over the past year.
Looking at the last year, ALGAE shows a very strong growth in Revenue. The Revenue has grown by 59.05%.
The Revenue has been growing by 43.52% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)55.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.36%
Revenue 1Y (TTM)59.05%
Revenue growth 3Y26.74%
Revenue growth 5Y43.52%
Sales Q2Q%20.35%

3.2 Future

The Earnings Per Share is expected to grow by 17.96% on average over the next years. This is quite good.
Based on estimates for the next years, ALGAE will show a very strong growth in Revenue. The Revenue will grow by 39.99% on average per year.
EPS Next Y30.77%
EPS Next 2Y30.09%
EPS Next 3Y27.59%
EPS Next 5Y17.96%
Revenue Next Year13.04%
Revenue Next 2Y50.36%
Revenue Next 3Y56.76%
Revenue Next 5Y39.99%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ALGAE.PA Yearly Revenue VS EstimatesALGAE.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20M 40M 60M 80M 100M
ALGAE.PA Yearly EPS VS EstimatesALGAE.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.2 -0.4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALGAE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALGAE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALGAE.PA Price Earnings VS Forward Price EarningsALGAE.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALGAE.PA Per share dataALGAE.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 0.3

4.3 Compensation for Growth

ALGAE's earnings are expected to grow with 27.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.09%
EPS Next 3Y27.59%

More info and screens

0

5. Dividend

5.1 Amount

ALGAE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FERMENTALG

EPA:ALGAE (10/7/2025, 7:00:00 PM)

0.4905

-0.01 (-1.11%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)09-11 2025-09-11
Earnings (Next)10-07 2025-10-07
Inst Owners24.45%
Inst Owner ChangeN/A
Ins Owners2.02%
Ins Owner ChangeN/A
Market Cap44.07M
Analysts84.44
Price Target0.73 (48.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-28.57%
EPS NY rev (3m)-12.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-20.25%
Revenue NY rev (3m)-20.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.45
P/FCF N/A
P/OCF N/A
P/B 1.45
P/tB 2.82
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0.14
BVpS0.34
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.56%
ROE -38.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.94%
FCFM N/A
ROA(3y)-23.5%
ROA(5y)-19.63%
ROE(3y)-36.23%
ROE(5y)-31.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.82%
GM growth 5YN/A
F-Score6
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.25%
Cap/Sales 3.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.88
Quick Ratio 1.83
Altman-Z 1.5
F-Score6
WACC6.14%
ROIC/WACCN/A
Cap/Depr(3y)32.24%
Cap/Depr(5y)108.18%
Cap/Sales(3y)12.02%
Cap/Sales(5y)34.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.36%
EPS Next Y30.77%
EPS Next 2Y30.09%
EPS Next 3Y27.59%
EPS Next 5Y17.96%
Revenue 1Y (TTM)59.05%
Revenue growth 3Y26.74%
Revenue growth 5Y43.52%
Sales Q2Q%20.35%
Revenue Next Year13.04%
Revenue Next 2Y50.36%
Revenue Next 3Y56.76%
Revenue Next 5Y39.99%
EBIT growth 1Y15.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.18%
EBIT Next 3Y33.56%
EBIT Next 5Y22.54%
FCF growth 1Y49.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.34%
OCF growth 3YN/A
OCF growth 5YN/A